Oppenheimer analyst Jay Olson raised the firm’s price target on Neurocrine to $200 from $170 and keeps an Outperform rating on the shares. The firm is “increasingly optimistic” for the company’s M4 agonist, NBI-‘568, ahead of Phase 2 topline results expected in the second half of 2024. Oppenheimer’s scenario analysis forecasts +30% upside upon ‘568 showing a competitive profile with 60% POS vs. -15% downside with 40% probability.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Voyager Therapeutics reports selection of gene therapy development candidate
- JPMorgan biotech analysts to hold an analyst/industry conference call
- Neurocrine price target raised to $159 from $128 at UBS
- Neurocrine price target raised to $164 from $157 at Guggenheim
- Neurocrine price target raised to $161 from $160 at Deutsche Bank
